The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
Whitney N. Goldsberry, Sarah S. Summerlin, Allison Guyton, Brittani Caddell, Warner K. Huh, Kenneth H. Kim, Margaret Liang
Topics & Concepts
MedicineMedical prescriptionPharmacyOlaparibFinanceMedicare Part DEmergency medicineInternal medicineFamily medicinePrescription drugBusinessPoly ADP ribose polymerasePharmacologyGenePolymeraseBiochemistryChemistryPARP inhibition in cancer therapyEconomic and Financial Impacts of CancerMedication Adherence and Compliance